Evidence map›Paper›PMID 34007170›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease

A Systematic Literature Review of the Humanistic Burden of COPD.

John R Hurst, Mohd Kashif Siddiqui, Barinder Singh, Precil Varghese, Ulf Holmgren, Enrico de Nigris

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. A Pilot Economic Evaluation of a Nature-Based Therapy for Chronic Obstructive Pulmonary Disease in Austria.International journal of environmental research and public health · 2026
    Trial
  5. Trial
  6. The Societal and Economic Burden of COPD in Saudi Arabia.Global journal on quality and safety in healthcare · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.International journal of chronic obstructive pulmonary disease · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John R HurstUCL Respiratory, University College London, London, UK.ORCID 0000-0002-7246-6040
Mohd Kashif SiddiquiHEOR and RWE Analytics, Regulatory Access, Parexel International Ltd, Mohali, India.ORCID 0000-0002-0214-8143
Barinder SinghHEOR Evidence Evaluation, Parexel International Ltd, Mohali, India.
Precil VargheseBiopharmaceuticals Medical, Respiratory and Immunology, AstraZeneca, Gothenburg, MD, USA.
Ulf HolmgrenReal World Science and Digital, Biopharmaceutical Medical, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-4602-9381
Enrico de NigrisGlobal Product and Portfolio Strategy, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, causing substantial economic and social burden.

objectiveThis review assessed the patient-reported humanistic burden associated with moderate to very severe COPD, specifically the impact on health-related quality of life (HRQoL), symptoms, limitations in daily life, and emotional implications, through the use of HRQoL instruments.

methodsA systematic review was conducted to retrieve relevant clinical data from published literature using a representative sample of countries where healthcare systems provide wide availability of COPD medications and/or universal coverage includes respiratory medicines (Australia, Canada, China, France, Germany, Italy, Spain, the UK, and the USA). The primary inclusion criteria were patients with moderate to very severe COPD. HRQoL was quantified with non-disease-specific and disease-specific questionnaires.

resultsIn total, 82 studies from 95 publications presented HRQoL data from patients with moderate to very severe COPD. Patient-reported HRQoL declined with worsening airflow limitation, advancing GOLD group, and increasing exacerbation frequency. Both increasing frequency of hospitalization for COPD exacerbations and recurrent hospitalization adversely impacted HRQoL. Comorbidity incidence was higher in patients with increased airflow limitation. It was associated with a further decline in HRQoL and increased depression and anxiety, particularly as disease-associated pain worsened. Physical activity improved HRQoL over time.

conclusionThis review highlighted the impact of exacerbations and associated hospitalizations on the humanistic burden of COPD. These findings underline the importance of managing COPD actively, including prompt and appropriate use of pharmacological and non-pharmacological therapies that can improve symptoms and reduce the risk of exacerbations, thereby lessening the humanistic burden. Future reviews could consider a broader range of countries and publications to further assess the humanistic impact of COPD in low- and middle-income economies.

Indexed as

Pulmonary Disease, Chronic ObstructiveQuality of LifeAustraliaCanadaChinaFranceGermanyHumansItalySpainchronic obstructive pulmonary diseasehumanistic burdenpatient-reported outcomesquality of life

Identifiers

PMID34007170
PMCPMC8121160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.